Chromosome 20p11 gains are associated with liver-specific metastasis in patients with colorectal cancer

Gut

Volumn 62, Issue 1, 2013, Pages 94-101

  Mekenkamp, Leonie J M ^a   Haan, Josien C ^b   Koopman, Miriam ^c   Vink Bor̈ger, M Elisa ^a   Israeli, Daniëlle ^b   Teerenstra, Steven ^a   Ylstra, Bauke ^b   Meijer, Gerrit A ^b   Punt, Cornelis J A ^a,d   Nagtegaal, Iris D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 20P; CHROMOSOME ABERRATION; CLINICAL FEATURE; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC GAIN; GENETIC MARKER; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; CHROMOSOME DUPLICATION; CHROMOSOMES, HUMAN, PAIR 20; COLORECTAL NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; GENETIC MARKERS; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84871105339     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301587     Document Type: Article

References (41)

1. Albini A, Mirisola V, Pfeffer U. Metastasis signatures: genes regulating tumor-microenvironment interactions predict metastatic behavior. Cancer Metastasis Rev 2008;27:75-83.
2. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
3. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721-7.
4. Hermanek P, Wiebelt H, Riedl S, et al. [Long-term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group]. Chirurg 1994;65:287-97.
5. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95. (Pubitemid 44781029)
6. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904. (Pubitemid 44175140)
7. Minn AJ, Gupta GP, Padua D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 2007;104:6740-5. (Pubitemid 47175571)
8. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49. (Pubitemid 36808649)
9. Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17. (Pubitemid 34704985)
10. Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 2000;83:431-7. (Pubitemid 30487852)
11. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106. (Pubitemid 33049527)
12. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-18. (Pubitemid 28510874)
13. Kemeny N, Braun DW Jr. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 1983;74:786-94. (Pubitemid 13080121)
14. Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009;27:2848-54.
15. Wils J, Blijham GH, Wagener T, et al. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer 2003;39:346-52. (Pubitemid 36140052)
16. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37. (Pubitemid 41095086)
17. Assersohn L, Norman A, Cunningham D, et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999;79:1800-5. (Pubitemid 29132308)
18. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135-42. (Pubitemid 47042893)
19. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
20. Hamilton S, Aaltonen L. WHO Classification of Tumours, Pathology & Genetics, Tumours of the Digestive System. Geneva: World health Organization, 2000.
21. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-73.
22. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
23. Brosens RP, Haan JC, Carvalho B, et al. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol 2010;221:411-24.
24. Buffart TE, Israeli D, Tijssen M, et al. Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer 2008;47:994-1004.
25. van de Wiel MA, Brosens R, Eilers PH, et al. Smoothing waves in array CGH tumor profiles. Bioinformatics 2009;25:1099-104.
26. van de Wiel MA, Kim KI, Vosse SJ, et al. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007;23:892-4. (Pubitemid 47049924)
27. Olshen AB, Venkatraman ES, Lucito R, et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
28. van de Wiel MA, Wieringen WN. CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Inform 2007;3:55-63. (Pubitemid 47075792)
29. van de Wiel MA, Smeets SJ, Brakenhoff RH, et al. CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics 2005;21:3193-4. (Pubitemid 41418483)
30. Bruin SC, He Y, Mikolajewska-Hanclich I, et al. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer 2011;105:281-7.
31. Mitry E, Guiu B, Cosconea S, et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010;59:1383-8.
32. Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 2010;16:4084-8.
33. Smith KJ, Jones PF, Burke DA, et al. Lymphatic vessel distribution in the mucosa and submucosa and potential implications for T1 colorectal tumors. Dis Colon Rectum 2011;54:35-40.
34. Mekenkamp LJ, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010; 103:159-64.
35. Nakao K, Shibusawa M, Ishihara A, et al. Genetic changes in colorectal carcinoma tumors with liver metastases analyzed by comparative genomic hybridization and DNA ploidy. Cancer 2001;91:721-6. (Pubitemid 32173296)
36. Hidaka S, Yasutake T, Takeshita H, et al. Differences in 20q13.2 copy number between colorectal cancers with and without liver metastasis. Clin Cancer Res 2000;6:2712-17. (Pubitemid 30482109)
37. Ilhan A, Gartner W, Nabokikh A, et al. Localization and characterization of the novel protein encoded by C20orf3. Biochem J 2008;414:485-95.
38. Utsunomiya T, Hara Y, Kataoka A, et al. Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival. Clin Cancer Res 2002;8:2591-4. (Pubitemid 34856345)
39. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101.
40. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008;133:66-77. (Pubitemid 351442989)
41. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.